PMID- 22185637
OWN - NLM
STAT- MEDLINE
DCOM- 20121029
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 53
IP  - 5
DP  - 2012 May
TI  - Stage IV and age over 45 years are the only prognostic factors of the 
      International Prognostic Score for the outcome of advanced Hodgkin lymphoma in 
      the Spanish Hodgkin Lymphoma Study Group series.
PG  - 812-9
LID - 10.3109/10428194.2011.635861 [doi]
AB  - The International Prognostic Score (IPS) is the most widely used system to date 
      for identifying risk groups for the outcome of patients with advanced Hodgkin 
      lymphoma, although important limitations have been recognized. We analyzed the 
      value of the IPS in a series of 311 patients with advanced classical Hodgkin 
      lymphoma (cHL) (Ann Arbor stage III, IV or stage II with B symptoms and/or bulky 
      masses) treated with first-line chemotherapy including adriamycin (adriamycin, 
      bleomycin, vinblastine, dacarbazine [ABVD] or equivalent variants). In univariate 
      and multivariate analyses, stage IV disease and age >/= 45 years were the only 
      factors with independent predictive significance for overall survival (OS) (p = 
      0.002 and p < 0.001, respectively). Stage IV was still significant for freedom 
      from progression (FFP) (p = 0.001) and age >/= 45 years was borderline significant 
      (p = 0.058). IPS separates prognostic groups, as in the original publication, but 
      this is mainly due to the high statistical significance of stage IV and age >/= 45 
      years. Moreover, the combination of these two factors enables a simpler system to 
      be constructed that separates groups with different FFP and OS. In conclusion, in 
      our series, stage IV and age >/= 45 years are the key prognostic factors for the 
      outcome of advanced cHL.
FAU - Guisado-Vasco, Pablo
AU  - Guisado-Vasco P
AD  - Hospital Ramon y Cajal , Madrid , Spain.
FAU - Arranz-Saez, Reyes
AU  - Arranz-Saez R
FAU - Canales, Miguel
AU  - Canales M
FAU - Canovas, Araceli
AU  - Canovas A
FAU - Garcia-Larana, Jose
AU  - Garcia-Larana J
FAU - Garcia-Sanz, Ramon
AU  - Garcia-Sanz R
FAU - Lopez, Andres
AU  - Lopez A
FAU - Lopez, Jose Luis
AU  - Lopez JL
FAU - Llanos, Marta
AU  - Llanos M
FAU - Moraleda, Jose Maria
AU  - Moraleda JM
FAU - Rodriguez, Jose
AU  - Rodriguez J
FAU - Rayon, Consuelo
AU  - Rayon C
FAU - Sabin, Pilar
AU  - Sabin P
FAU - Salar, Antonio
AU  - Salar A
FAU - Marin-Niebla, Ana
AU  - Marin-Niebla A
FAU - Morente, Manuel
AU  - Morente M
FAU - Sanchez-Godoy, Pedro
AU  - Sanchez-Godoy P
FAU - Tomas, Jose Francisco
AU  - Tomas JF
FAU - Muriel, Alfonso
AU  - Muriel A
FAU - Abraira, Victor
AU  - Abraira V
FAU - Piris, Miguel A
AU  - Piris MA
FAU - Garcia, Juan F
AU  - Garcia JF
FAU - Montalban, Carlos
AU  - Montalban C
CN  - Spanish Hodgkin Lymphoma Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20120131
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Hodgkin Disease/*diagnosis/*drug therapy
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Spain
MH  - Treatment Outcome
MH  - Young Adult
FIR - Ramos, R
IR  - Ramos R
FIR - Rodriguez, J
IR  - Rodriguez J
FIR - Mestre, F
IR  - Mestre F
FIR - Dominguez, P
IR  - Dominguez P
FIR - Jara, C
IR  - Jara C
FIR - Mestre, M J
IR  - Mestre M
FIR - Quiben, R
IR  - Quiben R
FIR - Mendez, M
IR  - Mendez M
FIR - Martinez, M A
IR  - Martinez M
FIR - Grande, C
IR  - Grande C
FIR - Garcia-Cosio, M
IR  - Garcia-Cosio M
FIR - Montalban, C
IR  - Montalban C
FIR - Garcia-Larana, J
IR  - Garcia-Larana J
FIR - Canales, M
IR  - Canales M
FIR - Alves, J
IR  - Alves J
FIR - Bellas, C
IR  - Bellas C
FIR - Provencio, M
IR  - Provencio M
FIR - Castano, A
IR  - Castano A
FIR - Sanchez-Godoy, P
IR  - Sanchez-Godoy P
FIR - Martin, C
IR  - Martin C
FIR - Martinez, R
IR  - Martinez R
FIR - Menarguez, J
IR  - Menarguez J
FIR - Sabin, P
IR  - Sabin P
FIR - Flores, E
IR  - Flores E
FIR - Gonzalez-Carrero, J
IR  - Gonzalez-Carrero J
FIR - Poderos, C
IR  - Poderos C
FIR - Salar, A
IR  - Salar A
FIR - Serrano, S
IR  - Serrano S
FIR - Romagosa, V
IR  - Romagosa V
FIR - Fernandez, A
IR  - Fernandez A
FIR - Mollejo, M
IR  - Mollejo M
FIR - Cruz, M A
IR  - Cruz M
FIR - Canovas, A
IR  - Canovas A
FIR - Camarero, C
IR  - Camarero C
FIR - Llanos, M
IR  - Llanos M
FIR - Arranz, R
IR  - Arranz R
FIR - Acevedo, A
IR  - Acevedo A
FIR - Garcia-Sanz, R
IR  - Garcia-Sanz R
FIR - Flores, T
IR  - Flores T
FIR - Morante, C
IR  - Morante C
FIR - Marin, A
IR  - Marin A
FIR - Rios, E
IR  - Rios E
FIR - Mazorra, F
IR  - Mazorra F
FIR - Conde, E
IR  - Conde E
FIR - Fresno, M F
IR  - Fresno M
FIR - Rayon, C
IR  - Rayon C
FIR - Nicolas, C
IR  - Nicolas C
FIR - Santonja, C
IR  - Santonja C
FIR - Lopez, Jose L
IR  - Lopez JL
FIR - Flores, T
IR  - Flores T
FIR - Garcia-Sanz, R
IR  - Garcia-Sanz R
FIR - Guma, J
IR  - Guma J
FIR - Gonzalvo, P
IR  - Gonzalvo P
FIR - Fernandez, G
IR  - Fernandez G
FIR - Forteza, J
IR  - Forteza J
FIR - Fraga, M
IR  - Fraga M
FIR - Bello, J L
IR  - Bello J
FIR - Bas, A
IR  - Bas A
FIR - Mendez, J R
IR  - Mendez J
FIR - Tomas, J F
IR  - Tomas JF
FIR - Estevez, M
IR  - Estevez M
FIR - Garcia, J F
IR  - Garcia J
FIR - Ruiz-Marcellan, C
IR  - Ruiz-Marcellan C
FIR - Lopez, A
IR  - Lopez A
FIR - Morente, M M
IR  - Morente M
FIR - Piris, M A
IR  - Piris M
EDAT- 2011/12/22 06:00
MHDA- 2012/10/30 06:00
CRDT- 2011/12/22 06:00
PHST- 2011/12/22 06:00 [entrez]
PHST- 2011/12/22 06:00 [pubmed]
PHST- 2012/10/30 06:00 [medline]
AID - 10.3109/10428194.2011.635861 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2012 May;53(5):812-9. doi: 10.3109/10428194.2011.635861. Epub 2012 
      Jan 31.